
MISHCHENKO et al.1836
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
10. Gong, T., et al. (2020) DAMP-sensing receptors in sterile inflammation and inflammatory diseases, Nat. Rev.
Immunol., 20, 95-112, https://doi.org/10.1038/s41577-019-0215-7.
11. Galluzzi, L., et al. (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee
on Cell Death 2018, Cell Death Differ., 25, 486-541, https://doi.org/10.1038/s41418-017-0012-4.
12. Aaes, T. L., et al. (2016) Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity, Cell
Rep., 15, 274-287, https://doi.org/10.1016/j.celrep.2016.03.037.
13. Galluzzi, L., et al. (2020) Consensus guidelines for the definition, detection and interpretation of immunogenic
cell death, J. Immunother. Cancer, 8, e000337, https://doi.org/10.1136/jitc-2019-000337.
14. Humeau, J., et al. (2019) Gold Standard assessment of immunogenic cell death in oncological mouse models,
Methods Mol. Biol., 1884, 297-315, https://doi.org/10.1007/978-1-4939-8885-3_21.
15. Mishchenko, T. A., et al. (2024) Gold standard assessment of immunogenic cell death induced by photodynamic
therapy: from in vitro to tumor mouse models and anti-cancer vaccination strategies, Methods Cell Biol., 183,
203-264, https://doi.org/10.1016/bs.mcb.2023.05.003.
16. Casares, N., et al. (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death, J. Exp.
Med., 202, 1691-1701, https://doi.org/10.1084/jem.20050915.
17. Krysko, D. V., et al. (2012) Immunogenic cell death and DAMPs in cancer therapy, Nat. Rev. Cancer, 12, 860-875,
https://doi.org/10.1038/nrc3380.
18. Kaczmarek, A., et al. (2013) Necroptosis: the release of damage-associated molecular patterns and its physiolog-
ical relevance, Immunity, 38, 209-223, https://doi.org/10.1016/j.immuni.2013.02.003.
19. Hadian, K., et al. (2023) The therapeutic potential of targeting regulated non-apoptotic cell death, Nat. Rev. Drug
Discov., 22, 723-742, https://doi.org/10.1038/s41573-023-00749-8.
20. Huang, C., et al. (2025) Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical per-
spectives, Mol. Cancer, 24, 131, https://doi.org/10.1186/s12943-025-02344-4.
21. Catanzaro, E., et al. (2024) Immunogenicity of ferroptosis in cancer: a matter of context? Trends Cancer, 10,
407-416, https://doi.org/10.1016/j.trecan.2024.01.013.
22. Li, J., et al. (2025) Immunogenic cuproptosis in cancer immunotherapy via an in situ cuproptosis-inducing sys-
tem, Biomaterials, 319, 123201, https://doi.org/10.1016/j.biomaterials.2025.123201.
23. Tsvetkov, P., et al. (2022) Copper induces cell death by targeting lipoylated TCA cycle proteins, Science, 375,
1254-1261, https://doi.org/10.1126/science.abf0529.
24. Hayashi, K., et al. (2021) Inhibitory DAMPs in immunogenic cell death and its clinical implications, Cell Stress,
5, 52-54, https://doi.org/10.15698/cst2021.04.247.
25. Chen, R., et al. (2022) The mechanism of HMGB1 secretion and release, Exp Mol Med, 54, 91-102, https://
doi.org/10.1038/s12276-022-00736-w.
26. Ostwald, T. J., et al. (1974) Isolation of a high affinity calcium-binding protein from sarcoplasmic reticulum,
J.Biol. Chem., 249, 974-979, https://doi.org/10.1016/S0021-9258(19)43026-3.
27. Waisman, D. M., et al. (1984) Identification of a novel hepatic calcium binding protein, Biochem. Biophys. Res.
Commun., 119, 440-446, https://doi.org/10.1016/s0006-291x(84)80268-5.
28. Okura, G.C., etal. (2024) Calreticulin-enigmatic discovery, Biomolecules, 14, 866, https://doi.org/10.3390/biom14070866.
29. Smith, M. J., et al. (1989) Multiple zones in the sequence of calreticulin (CRP55, calregulin, HACBP), a major
calcium binding ER/SR protein, EMBO J., 8, 3581-3586, https://doi.org/10.1002/j.1460-2075.1989.tb08530.x.
30. Okura, G. C., et al. (2025) Calreticulin-from the endoplasmic reticulum to the plasma membrane-adventures of
a wandering protein, Cancers (Basel), 17, 288, https://doi.org/10.3390/cancers17020288.
31. Gelebart, P., et al. (2005) Calreticulin, a Ca
2+
-binding chaperone of the endoplasmic reticulum, Int. J. Biochem.
Cell Biol., 37, 260-266, https://doi.org/10.1016/j.biocel.2004.02.030.
32. Michalak, M. (2024) Calreticulin: endoplasmic reticulum Ca
2+
gatekeeper, J. Cell Mol. Med., 28, e17839, https://
doi.org/10.1111/jcmm.17839.
33. Pikor, D., et al. (2024) Calcium ions in the physiology and pathology of the central nervous system, Int. J. Mol.
Sci., 25, 13133, https://doi.org/10.3390/ijms252313133.
34. Hossain, M. A., et al. (2000) Evidence of [Ca(2+)]i elevation by anti-calreticulin immunoreactive protein in neu-
rons, Neurosci Res, 36, 285-290, https://doi.org/10.1016/s0168-0102(99)00130-3.
35. Qiu, Y., et al. (2009) Transcriptional control of the calreticulin gene in health and disease, Int. J. Biochem. Cell
Biol., 41, 531-538, https://doi.org/10.1016/j.biocel.2008.06.020.
36. Rauch, F., et al. (2000) Heart, brain, and body wall defects in mice lacking calreticulin, Exp. Cell Res., 256, 105-
111, https://doi.org/10.1006/excr.2000.4818.
37. Taguchi, J., et al. (2000) Different expression of calreticulin and immunoglobulin binding protein in Alzheimer’s
disease brain, Acta Neuropathol., 100, 153-160, https://doi.org/10.1007/s004019900165.